CNBX Pharmaceuticals, Inc. (CNBX)

0.0001 0.00 (0.00%) USD  |  OTCM  |  Sep 24, 16:00
More

CNBX Pharmaceuticals Research and Development Expense (Quarterly)

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
February 28, 2026 0.00
November 30, 2025
August 31, 2025 0.00
May 31, 2025 0.00
February 28, 2025 0.00
November 30, 2024 0.00
August 31, 2024
May 31, 2024 0.0429M
February 29, 2024 0.1072M
November 30, 2023 0.1124M
August 31, 2023 0.0932M
May 31, 2023 0.2631M
February 28, 2023 0.0123M
November 30, 2022 0.0629M
August 31, 2022 0.1636M
May 31, 2022 0.2491M
February 28, 2022 0.3306M
November 30, 2021 0.44M
August 31, 2021 0.471M
May 31, 2021 0.5508M
February 28, 2021 0.316M
November 30, 2020 0.4337M
August 31, 2020 0.4019M
May 31, 2020 0.3701M
February 29, 2020 0.4444M
Date Value
November 30, 2019 0.466M
August 31, 2019 0.4778M
May 31, 2019 0.3338M
February 28, 2019 0.428M
November 30, 2018 0.3042M
August 31, 2018 0.4229M
May 31, 2018 0.2635M
February 28, 2018 0.1052M
November 30, 2017 0.2123M
August 31, 2017 0.1101M
May 31, 2017 0.0682M
February 28, 2017 0.0465M
November 30, 2016 0.0221M
August 31, 2016 0.0551M
May 31, 2016 0.0155M
February 29, 2016 0.0986M
November 30, 2015 0.0084M
August 31, 2015 0.0551M
May 31, 2015 0.0712M
February 28, 2015 0.0128M
November 30, 2014 0.0003M
May 31, 2014
February 28, 2014 0.00
November 30, 2013 0.00
August 31, 2013 0.00

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 2.142M
GB Sciences, Inc. --
Arvinas, Inc. 52.30M
Fulcrum Therapeutics, Inc. 12.23M
Definium Therapeutics, Inc. 48.66M